286 related articles for article (PubMed ID: 30902440)
21. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
Fokam J; Ngoufack Jagni Semengue E; Armenia D; Takou D; Dambaya B; Teto G; Chenwi CA; Nka AD; Beloumou GA; Ndjeyep SCD; Tchouaket MCT; Fainguem N; Sosso SM; Colizzi V; Perno CF; Ndjolo A; Ceccherini-Silberstein F; Santoro MM
Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115574. PubMed ID: 34864527
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
Semengue ENJ; Santoro MM; Ndze VN; Dambaya B; Takou D; Teto G; Nka AD; Fabeni L; Wiyeh A; Ceccherini-Silberstein F; Colizzi V; Perno CF; Fokam J
Syst Rev; 2020 Apr; 9(1):93. PubMed ID: 32334643
[TBL] [Abstract][Full Text] [Related]
23. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
24. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
Sangaré MN; Baril JG; de Pokomandy A; Laprise C; Deshaies C; Klein M; Thomas R; Tremblay C; Roger M; Pexos C; Greenwald Z; Machouf N; Durand M; Hardy I; Dakouo M; Laporte L; Trottier H
Medicine (Baltimore); 2020 Nov; 99(47):e23335. PubMed ID: 33217873
[TBL] [Abstract][Full Text] [Related]
25. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.
Giacomelli A; Ranzani A; Oreni L; Gervasi E; Lupo A; Ridolfo AL; Galli M; Rusconi S
Drug Des Devel Ther; 2019; 13():2271-2282. PubMed ID: 31371921
[TBL] [Abstract][Full Text] [Related]
26. COPEDOL: A two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen.
Landman R; Marcelin AG; Bennani M; Philippe C; Kousignian P; Finkielsztejn L; Roustand L; Nachbaur G; Pourcher V
Infect Dis Now; 2022 Mar; 52(2):93-100. PubMed ID: 34922034
[TBL] [Abstract][Full Text] [Related]
27. Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
Frange P; Blanche S; Veber F; Avettand-Fenoel V
HIV Med; 2021 Nov; 22(10):958-964. PubMed ID: 34369051
[TBL] [Abstract][Full Text] [Related]
28. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
29. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
Romo ML; Patel RC; Edwards JK; Humphrey JM; Musick BS; Bernard C; Maina MW; Brazier E; Castelnuovo B; Penner J; Wyka K; Cardoso SW; Ly PS; Kunzekwenyika C; Cortés CP; Panczak R; Kelvin EA; Wools-Kaloustian KK; Nash D;
Ann Intern Med; 2022 Jan; 175(1):84-94. PubMed ID: 34843382
[TBL] [Abstract][Full Text] [Related]
30. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
Revollo B; Viñuela L; de la Mora L; García F; Noguera-Julián M; Parera M; Paredes R; Llibre JM
J Antimicrob Chemother; 2022 May; 77(6):1738-1740. PubMed ID: 35274144
[TBL] [Abstract][Full Text] [Related]
31. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
[TBL] [Abstract][Full Text] [Related]
32. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
[TBL] [Abstract][Full Text] [Related]
33. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
34. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
Makonokaya L; Maida A; Kalitera LU; Wang A; Kapanda L; Kayira D; Bottoman M; Nkhoma H; Dunga S; Joaki Z; Chamanga R; Nkanaunena K; Hrapcak S; Nyirenda R; Chiwandira B; Maulidi M; Woelk G; Machekano R; Maphosa T
AIDS Behav; 2024 Jun; 28(6):2148-2155. PubMed ID: 38615099
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
36. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
[TBL] [Abstract][Full Text] [Related]
38. Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment Program.
Kanise H; van Oosterhout JJ; Bisani P; Songo J; Matola BW; Chipungu C; Simon K; Cox C; Hosseinipour MC; Sagno JB; Hoffman RM; Wallrauch C; Phiri S; Steegen K; Jahn A; Nyirenda R; Heller T
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257730
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
Tebano G; Soulié C; Schneider L; Blanc C; Agher R; Seang S; Valantin MA; Palich R; Tubiana R; Peytavin G; Marcelin AG; Assoumou L; Katlama C
J Antimicrob Chemother; 2020 Mar; 75(3):675-680. PubMed ID: 31800056
[TBL] [Abstract][Full Text] [Related]
40. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.
Brenner BG; Wainberg MA
Virus Res; 2017 Jul; 239():1-9. PubMed ID: 27422477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
